Voyager Therapeutics, Inc. announced on October 20, 2026, that Robin Swartz has been appointed President of the company, effective immediately. The appointment comes as part of a leadership transition plan where Swartz is expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer following the anticipated receipt of initial acute safety data in the first quarter of 2027 regarding its clinical trial of VY1706 in adults with early Alzheimer’s Disease. Sandrock will continue to serve on the Board of Directors following the transition.
Swartz, age 56, has served as Voyager’s Chief Operating Officer and Chief Business Officer since November 2024 and as Principal Financial Officer and Treasurer since May 2026. Her previous experience includes roles at Sanofi Genzyme, where she served as Senior Vice President, Head of Global and US Business Operations from June 2015 to December 2017.
In connection with the appointment, Swartz entered into an amended and restated employment agreement. Under the agreement, she is entitled to an annualized base salary of $625,000 and a target annual cash bonus of 50% of her base salary. Additionally, the Board approved the grant of a stock option to purchase 318,500 shares and a restricted stock unit award for 68,250 shares, both effective November 1, 2026. The option award has a ten-year term and vests over four years, while the restricted stock units vest over three years.
The agreement outlines severance benefits in the event of termination without cause or for good reason, including continued salary for 12 months and acceleration of equity awards in the event of a sale event.
